These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma. Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919 [TBL] [Abstract][Full Text] [Related]
25. Investigating Glycol-Split-Heparin-Derived Inhibitors of Heparanase: A Study of Synthetic Trisaccharides. Ni M; Elli S; Naggi A; Guerrini M; Torri G; Petitou M Molecules; 2016 Nov; 21(11):. PubMed ID: 27886097 [TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical expression of heparanase isoforms and syndecan-1 proteins in colorectal adenomas. Waisberg J; Theodoro TR; Matos LL; Orlandi FB; Serrano RL; Saba GT; Pinhal MA Eur J Histochem; 2016 Feb; 60(1):2590. PubMed ID: 26972718 [TBL] [Abstract][Full Text] [Related]
27. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Takebe N; Cheng X; Wu S; Bauer K; Goloubeva OG; Fenton RG; Heyman M; Rapoport AP; Badros A; Shaughnessy J; Ross D; Meisenberg B; Tricot G Clin Cancer Res; 2004 Dec; 10(24):8301-8. PubMed ID: 15623606 [TBL] [Abstract][Full Text] [Related]
28. Poly(N-acryl amino acids): a new class of biologically active polyanions. Bentolila A; Vlodavsky I; Ishai-Michaeli R; Kovalchuk O; Haloun C; Domb AJ J Med Chem; 2000 Jun; 43(13):2591-600. PubMed ID: 10891119 [TBL] [Abstract][Full Text] [Related]
29. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation. Okabe S; Tanaka Y; Tauchi T; Ohyashiki K Ann Hematol; 2019 Mar; 98(3):723-733. PubMed ID: 30430191 [TBL] [Abstract][Full Text] [Related]
30. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma. Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656 [TBL] [Abstract][Full Text] [Related]
31. Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma. Magill L; Lynas J; Morris TC; Walker B; Irvine AE Haematologica; 2004 Dec; 89(12):1428-33. PubMed ID: 15590391 [TBL] [Abstract][Full Text] [Related]
32. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Ferro V; Dredge K; Liu L; Hammond E; Bytheway I; Li C; Johnstone K; Karoli T; Davis K; Copeman E; Gautam A Semin Thromb Hemost; 2007 Jul; 33(5):557-68. PubMed ID: 17629854 [TBL] [Abstract][Full Text] [Related]
33. [Proteasome inhibition: a new therapeutic approach for the treatment of multiple myeloma]. Mikala G; Jákó J; Vályi-Nagy I Orv Hetil; 2004 Jan; 145(2):67-74. PubMed ID: 14978877 [TBL] [Abstract][Full Text] [Related]
34. [Research progress of heparinase in the field of medicine]. Liu W; Jiang Y; Zhao L; Zhang P; Wang S Sheng Wu Gong Cheng Xue Bao; 2018 Dec; 34(12):1953-1962. PubMed ID: 30584706 [TBL] [Abstract][Full Text] [Related]
35. Targeting PADI2 could stop the progression of myeloma. Tanday S Lancet Oncol; 2016 Aug; 17(8):e325. PubMed ID: 27425813 [No Abstract] [Full Text] [Related]
36. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Lapierre F; Holme K; Lam L; Tressler RJ; Storm N; Wee J; Stack RJ; Castellot J; Tyrrell DJ Glycobiology; 1996 Apr; 6(3):355-66. PubMed ID: 8724143 [TBL] [Abstract][Full Text] [Related]
37. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190 [TBL] [Abstract][Full Text] [Related]
38. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Bandari SK; Purushothaman A; Ramani VC; Brinkley GJ; Chandrashekar DS; Varambally S; Mobley JA; Zhang Y; Brown EE; Vlodavsky I; Sanderson RD Matrix Biol; 2018 Jan; 65():104-118. PubMed ID: 28888912 [TBL] [Abstract][Full Text] [Related]
39. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. Knopf KB; Duh MS; Lafeuille MH; Gravel J; Lefebvre P; Niculescu L; Ba-Mancini A; Ma E; Shi H; Comenzo RL Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):380-8. PubMed ID: 25023616 [TBL] [Abstract][Full Text] [Related]
40. Mass spectrometric evidence of heparin disaccharides for the catalytic characterization of a novel endolytic heparinase. Chao YP; Xiong SX; Cheng X; Qian S Acta Biochim Biophys Sin (Shanghai); 2004 Dec; 36(12):840-4. PubMed ID: 15592652 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]